Precision oncology is shifting toward comprehensive transcriptome profiling to reveal fusions, splice variants, and expression changes that DNA panels miss. Yet obtaining reliable data from degraded ...

Researchers studying gene expression have access to vast amounts of data from cells or tissues. This is thanks to advances in bulk and single-cell RNA-sequencing (RNA-seq) technologies that can ...

Qlucore, listed on Nasdaq First North, is launching a new Qlucore Insights test (Research Use Only) specifically developed for bladder cancer samples. The software-based test delivers multiple ...

Functional Characterization of Variants of Unknown Significance of Fibroblast Growth Factor Receptors 1-4 and Comparison With AI Model–Based Prediction An economic model was developed to estimate the ...

Parse Biosciences, a QIAGEN company and the leading provider of scalable and accessible single-cell sequencing solutions, today announced the commercial availability of Evercode (TM) Whole ...

The software‑based test delivers multiple clinically relevant results from a single whole‑transcriptome sequencing run, including detection of samples with high levels of the important MECOM gene.

Illumina has unveiled a new spatial technology that is designed to unlock further sequencing capabilities for researchers. Due for release in 2026, the US company’s technology for whole-transcriptome ...

We validated a clinical bait-capture WTS assay using 78 solid tumor samples across diverse tissue types, including 59 with known fusions or oncogenic splice variants. Sensitivity was assessed against ...